×
Aktivieren Sie Javascript in Ihrem Browser, um unsere Webseite optimal zu nutzen.
CTLA4 Antikörper (N-Term)
CTLA4
Reaktivität: Human
WB, IHC (p), EIA
Wirt: Kaninchen
Polyclonal
unconjugated
Produktdetails anti-CTLA4 Antikörper
(ausblenden)
Target
Alle CTLA4 Antikörper anzeigen
CTLA4
(Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))
Bindungsspezifität
Alle Epitope für CTLA4 Antikörper
AA 57-86, N-Term
Reaktivität
Alle Reaktivitäten für CTLA4 Antikörper
Human
Wirt
Alle Wirte für CTLA4 Antikörper
Kaninchen
Klonalität
Alle Klonalitäten für CTLA4 Antikörper
Polyklonal
Konjugat
Alle Konjugate für CTLA4 Antikörper
Dieser CTLA4 Antikörper ist unkonjugiert
Applikation
Alle Applikationen für CTLA4 Antikörper
Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)
Spezifität
This antibody recognizes Human CD152 / CTLA4 (N-term).
Aufreinigung
Affinity Chromatography on Protein A
Immunogen
KLH conjugated synthetic peptide between 57-86 amino acids from the N-terminal region of Human CD152 / CTLA4. Genename: CTLA4
Isotyp
Ig Fraction
Top Product
Discover our top product CTLA4 Primärantikörper
Alternativen
(anzeigen)
Anwendungsinformationen
(ausblenden)
Applikationshinweise
Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Handhabung
(ausblenden)
Format
Liquid
Konzentration
0.25 mg/mL
Buffer
PBS, 0.09 % Sodium Azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Referenzen für anti-CTLA4 Antikörper (ABIN951196)
(ausblenden)
Karpathiou, Chauleur, Hathroubi, Habougit, Peoch : "Expression of CD3, PD-L1 and CTLA-4 in mammary and extra-mammary Paget disease. " in: Cancer immunology, immunotherapy : CII , Vol. 67 , Issue 8 , pp. 1297-1303 , (2018 ) (PubMed ).
Karpathiou, Casteillo, Giroult, Forest, Fournel, Monaya, Froudarakis, Dumollard, Prades, Peoch : "Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics. " in: Oncotarget , Vol. 8 , Issue 12 , pp. 19310-19322 , (2017 ) (PubMed ).
Details zu CTLA4
(ausblenden)
Target
CTLA4
(Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))
Andere Bezeichnung
CD152 / CTLA4 (CTLA4 Produkte )
Hintergrund
CTLA4 is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases.Synonyms: CTLA-4, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4
Molekulargewicht
24656 Da
Gen-ID
1493
NCBI Accession
NP_001032720
Pathways
Cancer Immune Checkpoints
Zuletzt angesehen
(ausblenden)